罗格列酮抑制人胃腺癌SGC7901增殖机制的研究

目的：探讨在体外不同浓度的过氧化物酶体增殖物激活受体γ（PPARγ）激动剂罗格列酮（ROZ）对人胃癌细胞系SGC7901的生长及细胞周期的影响。方法：采用MTT法比色实验、集落形成实验、电子显微镜,透射电镜,流式细胞仪分别观察不同浓度罗格列酮0.08μmol/L,0.4μmol/L,2μmol/L,10μmol/L,50μmol/L,作用于SGC7901细胞,对细胞增殖,细胞形态和细胞周期的影响。结果：ROZ可抑制SGC7901细胞的生长以及SGC7901细胞集落的形成,并呈现剂量依赖性,其半数抑制浓度（IC50）约为50μmol/L。透射电镜低倍镜以及高倍下可见凋亡细胞。流式细胞仪结果显示,ROZ可抑制SGC7901细胞,引起G0/G1期细胞大量增加,S期细胞减少,且细胞周期停滞于G1期。结论：ROZ具有抗肿瘤作用,能够抑制SGC7901细胞的增殖并诱导凋亡,这种作用与其诱导细胞周期G0/G1期的停滞和诱导凋亡作用有关。因此,ROZ有望成为胃癌治疗的辅助用药亦或治疗药,PPARγ有潜力成为肿瘤治疗的新靶点。

A Study on the Mechanism of Growth Inhibition by Rosiglitazone in the Human Gastric Cancer Cell Line SGC7901

Objective： To investigate the mechanism of peroxisome proliferator-activated receptor-γ（PPAR-γ） agonist rosiglitazone（ROZ） which inhibited cell proliferation and cell cycle of human gastric carcinoma cell line SGC7901 in vitro. Methods： MTT colorimetric assay, colony formation assay, electron microscopy, transmission electron microscopy, flow cytometry were respectively used to determine the influence of different concentration of ROZ： 0.08 μmol/L, 0.4 μmol/L, 2 μmol/L, 10 μmol/L, 50 μmol/L which effected the gastric carcinoma cell line SGC7901 in the proliferation and cell cycle. Results： ROZ could inhibit the increase rates of gastric carcinoma cell line SGC7901 and the clone formation of SGC7901 and showed dose dependent. The half inhibitory concentration（IC50） was about 50 μmol/L. Transmission electron microscopy can be used to observe the apoptotic cells. Flow cytometry results showed that, ROZ could inhibit SGC7901 cells, induce a substantial increase of cells in G0/G1 phase, S phase cells decreased, and cell arrest in G1 phase. Conclusion： ROZ has the effect of antitumor, and it can inhibit the cell proliferation and induce apoptosis of the gastric carcinoma cell line SGC7901. The effect was related with G1 phase arresting of cell cycle and cell apoptosis. Therefore, ROZ is expected to become the assistant drug or treatment drug in the treatment of gastric cancer. PPAR-γ has the potential to become a new target of tumor treatment.